Auris Medical Holding Ltd.
(NASDAQ : EARS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.34%198.271.3%$525.37m
GILDGilead Sciences, Inc.
1.51%66.960.9%$355.84m
ALXNAlexion Pharmaceuticals, Inc.
0.95%106.672.0%$330.88m
ILMNIllumina, Inc.
0.61%307.053.5%$317.83m
BIIBBiogen Inc.
2.42%241.331.3%$313.48m
CELGCelgene Corporation
0.54%99.481.3%$296.14m
VRTXVertex Pharmaceuticals Incorporated
1.69%179.111.9%$177.69m
AAgilent Technologies, Inc.
0.60%78.541.6%$176.92m
REGNRegeneron Pharmaceuticals, Inc.
3.10%295.032.6%$171.54m
SRPTSarepta Therapeutics, Inc.
-2.79%82.9814.6%$141.19m
EXASExact Sciences Corporation
0.09%103.5024.1%$138.88m
ACADACADIA Pharmaceuticals Inc.
-1.01%41.2613.9%$124.18m
INCYIncyte Corporation
2.65%80.192.5%$87.46m
ALDRAlder Biopharmaceuticals, Inc.
0.05%18.6710.2%$76.45m
BMRNBioMarin Pharmaceutical Inc.
-0.26%75.804.3%$75.42m

Company Profile

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The firm focuses on the development of intranasal betahistine for the treatment of vertigo and for the prevention of antipsychotic-induced weight gain and somnolence. It also includes other programs under development such as Keyzilen, for the treatment of acute inner ear tinnitus; and Sonsuvi, for the treatment of acute inner ear hearing loss. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.